Neko Health raised $700 million to expand preventive diagnostics into the US market, building a longitudinal health dataset aimed at detecting disease before symptom onset. The funding reflects investor confidence that scalable preventive infrastructure and continuous data collection, rather than breakthrough therapeutics alone, will shape the future of longevity medicine.
Key Points
- Over 100,000 completed scans generating longitudinal health dataset for early disease detection
- Five of seven key biomarkers improved significantly between repeat scans in returning members
- US expansion tests whether consumer diagnostics can become evidence-generating platform, not just qu
Longevity Analysis
The infrastructure Neko is building addresses a foundational shift in how longevity medicine operates: from reactive intervention to continuous signal monitoring. By integrating wearable data with clinical diagnostics across repeat assessments, the company is establishing a framework for detecting when physiological systems begin to drift from baseline — capturing the window before pathology becomes clinically apparent. This approach recognizes that disease trajectory is influenced long before diagnosis, requiring the ability to track how breath, circulation, energy production, and metabolic function change over time. The real value lies not in the scanners themselves but in the dataset: evidence that links early biomarker shifts to long-term health outcomes, which can then inform whether routine screening actually reduces disease incidence and extends healthy lifespan. Whether this model generates that evidence at scale will determine whether preventive diagnostics evolves from consum
Original published by Longevity.Technology, by Eleanor Garth.